



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/831,679	05/10/2001	Petrus Johannes Lenting	20560-32	9980
25204	7590	02/11/2004	EXAMINER	
OPPENHEIMER WOLFF & DONNELLY LLP 840 NEWPORT CENTER DRIVE SUITE 700 NEWPORT BEACH, CA 92660				LIU, SAMUEL W
		ART UNIT		PAPER NUMBER
		1653		

DATE MAILED: 02/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/831,679	LENTING ET AL.
	Examiner	Art Unit
	Samuel W Liu	1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 31 December 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 20-28 is/are pending in the application.
4a) Of the above claim(s) none is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 20-28 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a))

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____
4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____ .
5) Notice of Informal Patent Application (PTO-152)
6) Other: _____

DETAILED ACTION

Status of the claims

Claims 20-28 are pending.

Applicants' amendment filed 31 December 2003, which cancels claims 1-19 and adds new claims 20-28 has been entered. Also, applicants' request (filed 31 December 2003) for extension of time of three months has been entered.

Also, note that applicants' submission of the certified copy of Austrian priority application A 1872/1988 (filed 10 November 2998) has been received.

The following Office Action is applicable to the pending claims 20-28.

Please note that grounds of objection and/or rejection not explicitly restated and/or set forth below are withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter that the applicant regards as his invention.

Claims 20-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 20 is indefinite because the recited portion designated by the amino acid residue numbers (e.g., 1743 (Phe) to 1749 (Arg)) *varies* with the *species* from which the polypeptide is isolated. Note that the residue numbering of Factor VIII polypeptide from human differs from that from mouse (see the amino acid sequence comparison between human, mouse and pig

shown in Figure 1, US Pat. No. 5859204). See also claims 21-22, 24 and 26-27. The dependent claims are also rejected.

Claim 25 is indefinite because the claim recitation is incomplete (there is no period “.” after “...binding site”).

To advance the prosecution, the Examiner has noted that the A1, A2, A3, C1 and C2 parameters set forth in the claims correspond to the regions

Claim Rejections - 35 USC §102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 20 and 23 rejected under 35 U.S.C. 102(b) as being anticipated by Pipe S. W. et al. (*J. Biol. Chem.* (1996) 271, 25671-25676) as is evidenced by the known fact shown by Lollar, J. S. (US Pat. No. 5859204).

Claims 20 and 22 are rejected under 35 U.S.C. 102(e) as being anticipated by Lollar, J. S. (US Pat. No. 5859204).

Lollar et al. teach that A3 domain (human) (residues 1690-2030) and C2 domain (human) (residues 21733-2332) (see Figure 1F and 1H). Also, Lollar et al. teach substitution of entire human A3 domain and human C2 domain by the corresponding porcine (pig) A3 domain and porcine C2 domain, respectively (see column 19, line 50, and Figure 1). The above Lollar et al. teachings meet the limitations set forth in claims 20 and 22 of the current application.

Thus, Lollar et al. patent anticipates the application claims 20 and 22.

Conclusion

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Wei Liu whose telephone number is 571-272-0949. The examiner can normally be reached from 9:00 a.m. to 5:00 p.m. on weekdays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low, can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703 308-4242 or 703 872-9306 (official) or 703 872-9307 (after final). Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 305-4700.



KAREN COCHRANE CARLSON, PH.D
PRIMARY EXAMINER



Samuel Wei Liu, Ph.D.

February 3, 2004